Walton Oaks and London, 16th Sept 2021: Pfizer UK has announced a partnership with British virtual oncology company, Entia, to accelerate development of a digitally enabled home blood monitoring service for breast cancer patients.
Entia’s virtual oncology platform enables patients to perform their own blood tests, with results viewable by their healthcare teams for remote monitoring. Together, Pfizer and Entia will partner to support healthcare professionals access this breakthrough innovative solution for NHS metastatic breast cancer clinics. This aims to help improve patient quality of life by reducing the burden of travelling for blood monitoring tests and unlock healthcare system capacity. The platform is currently in late stage development with required regulatory approvals anticipated for the UK and EU in early 2022.
Entia’s solution has been developed with patient and healthcare professional input through trials overseen by Europe’s largest single-site cancer centre, The Christie NHS Foundation Trust in Manchester and supported by UK Research and Innovation (UKRI). Entia’s solution includes individualised training and support for patients who use the device and data visualisation tools for healthcare professionals to ensure the solution unlocks capacity within healthcare systems and enhances the delivery of care.
"Living with cancer is hard enough for people and so it's important that we try to relieve the burden of treatment monitoring, as well as helping our already stretched healthcare services. We're excited to partner with Entia to do this for people living with metastatic breast cancer." said Erling Donnelly, Pfizer UK Oncology Lead. “Partnering with digital health and monitoring experts such as Entia will further support Pfizer’s breakthrough therapies in an area where the burden of living with cancer is significant.”
Entia’s founder and CEO Dr. Toby Basey-Fisher said “We founded Entia with the belief that we could significantly improve the lives of people during cancer treatment. We knew that by combining virtual services with our blood monitoring technology that we could truly transform the way cancer care is delivered in a reliable way. Pfizer recognise the incredible journey we are on and how combining our approach with life-changing treatments empowers patients with even more freedom to live their life how they choose. Importantly, our approach also aims to free up capacity and streamline clinical services by integrating with existing practice.”
